retatrutide clinical trial belgium Research Concentration Overview Retatrutide Phase 3: TRIUMPH Program

Translating these findings to humans, patients on semaglutide often experience reduced cortisol-related cravings, improved emotional eating patterns, and steadier energy levelsoutcomes consistent with better HPA axis balance

Mechanisms of Action Retatrutide activates three key receptors to modulate energy balance, appetite, and metabolism, leading to profound weight loss and glycemic control.[1][2] This triple agonism differentiates it from dual agonists like tirzepatide, enhancing fat oxidation and insulin sensitivity.[3][10] Key sub-mechanisms include: GLP-1 Receptor Activation : Suppresses appetite, delays gastric emptying, and promotes insulin secretion in a glucose-dependent manner.[1][11] GIP Receptor Activation : Enhances insulinotropic effects and improves beta-cell function, contributing to postprandial glucose control.[2][12] Glucagon Receptor Activation : Increases energy expenditure, promotes lipolysis, and supports hepatic fat reduction without significant hyperglycemia.[1][13] Synergistic Metabolic Regulation : Combines receptor effects to amplify weight loss through reduced caloric intake and increased thermogenesis.[3][14] Cardiometabolic Protection : Improves lipid profiles and reduces inflammation via multi-pathway modulation.[4][15] These mechanisms highlight Retatrutide's potential for compounding in therapies targeting obesity and related comorbidities

And how long do you need to stay on semaglutide to reap the rewards

FOR PULMONARY ASPIRATION SOURCE: DailyMed

Eligibility criteria for NHS-funded GLP-1 treatment for weight management include: For semaglutide (Wegovy): BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity For liraglutide (Saxenda): Similar BMI criteria as defined in NICE TA664 Evidence of previous weight management attempts through lifestyle modification Treatment must be initiated within specialist weight management services (Tier 3) Time-limited use as specified in the relevant NICE guidance The referral pathway typically involves: Initial GP consultation: Discuss weight concerns, document BMI and comorbidities, and review previous weight management efforts Tier 2/3 weight management services: Many areas require participation in structured lifestyle programmes before pharmacological intervention Specialist assessment: Referral to specialist weight management services for treatment initiation Ongoing monitoring: Regular review to assess response, tolerability, and continuation criteria Treatment continuation requires achieving the weight loss thresholds specified in the product-specific NICE guidance and SmPCs

Orforglipron could be available in the U.S